Skip to main content

Table 2 Effect of MEK162/BKM120 combination and BIBW2997/ARQ197 combination therapy on NSCLC H1975, H460, and A549 cell cycle distribution

From: Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

Group

Cell cycle distribution (%)

G0/G1

S

G2/M

H1975 cells

   

Control

61.5 + 3.6

29.4 + 2.3

9.1 + 6.3

BKM120 + MEK162

81.3 + 2.7*

12.9 + 6.5

5.8 + 2.2

BIBW2992 + ARQ197

92.6 + 5.5*#

3.5 + 2.4

3.9 + 1.4

H460 cells

   

Control

58.4 + 6.6

24.4 + 8.3

17.2 + 7.3

BKM120 + MEK162

90.5 + 3.8*▲

6.1 + 5.2

3.4 + 3.2

BIBW2992 + ARQ197

59.5 + 5.6#▲

22.7 + 3.4

17.8 + 7.4

A549 cells

   

Control

63.1 + 9.1

25.7 + 6.3

11.2 + 4.3

BKM120 + MEK162

85.3 + 7.6*&

8.8 + 2.5

5.9 + 3.8

BIBW2992 + ARQ197

61.4 + 5.5#▲

27.1 + 6.4

11.5 + 6.4

  1. H1975, H460, and A549 cells were treated with 1 μM MEK162/5 μM BKM120 combination and 1 µM BIBW2992 (EGFR inhibitor)/2 µM ARQ 197 (MET inhibitor) combination for 48 h. Control cells were treated with 0.05% DMSO. Each value represents mean ± SD obtained from three independent experiments
  2. *P < 0.05 vs. Control; #P < 0.05 vs. BKM120 + MEK162; ▲P < 0.05 vs. H1975 cells; &P < 0.05 vs. H460 cells under the same cell cycle phase and the same drug treatment
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us